|
COPS5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.05909999659204E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.90420000004232E-06 |
| Normal-vs-Stage2 |
4.798400E-03 |
| Normal-vs-Stage3 |
6.48009979009601E-10 |
| Normal-vs-Stage4 |
3.28030003160507E-09 |
| Stage1-vs-Stage2 |
8.446200E-01 |
| Stage1-vs-Stage3 |
1.760110E-03 |
| Stage1-vs-Stage4 |
2.564600E-03 |
| Stage2-vs-Stage3 |
3.082500E-02 |
| Stage2-vs-Stage4 |
1.527580E-02 |
| Stage3-vs-Stage4 |
6.152000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.1932999860752E-10 |
| Normal-vs-AfricanAmerican |
5.199100E-03 |
| Normal-vs-Asian |
1.736520E-03 |
| Caucasian-vs-AfricanAmerican |
9.763600E-01 |
| Caucasian-vs-Asian |
1.073780E-02 |
| AfricanAmerican-vs-Asian |
2.465600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.51069999843045E-08 |
| Normal-vs-Female |
7.62949999844054E-08 |
| Male-vs-Female |
2.635400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.24949999996882E-06 |
| Normal-vs-Age(41-60Yrs) |
1.94150000520921E-08 |
| Normal-vs-Age(61-80Yrs) |
2.98370000040293E-07 |
| Normal-vs-Age(81-100Yrs) |
2.838800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.159800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.998010E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.141800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.072600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.140400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.882400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.160100E-02 |
| Classical-VS-Follicular |
7.864300E-03 |
| Classical-VS-Other |
7.333400E-01 |
| Classical-VS-Normal |
1.00379999867783E-08 |
| Tall-VS-Follicular |
3.433900E-04 |
| Tall-VS-Other |
1.646240E-01 |
| Tall-VS-Normal |
1.2991000053475E-08 |
| Follicular-VS-Other |
5.614200E-01 |
| Follicular-VS-Normal |
4.291800E-02 |
| Other-VS-Normal |
4.461800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.59849999995065E-06 |
| Normal-vs-N1 |
2.11270000383124E-08 |
| N0-vs-N1 |
1.750050E-02 |
|
|
